ImmunityBio, Inc.
For the period ended Jun 11, 2024. Filed Apr 29, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 11, 2024 · Filed Apr 29, 2024
Contents
Pay Versus Performance Table
year.
Pay Versus Performance Table
| Value ofInitial Fixed$100 InvestmentBased On:_________________TotalShareholderReturn ($) (5)(f) | ||||||
|---|---|---|---|---|---|---|
| Year(a) · SummaryCompensationTable Totalfor PEO ($) (1) (2) (3)(b) · CompensationActually Paidto PEO ($) (4)(c) · AverageSummaryCompensationTable Totalfor Non-PEO NEOs ($) (1) (2) (3)(d) · AverageCompensation Actually Paidto Non-PEO NEOs ($) (4)(e) · Net Loss ($M) (6)(h) | ||||||
| 2023 | 1,156,903 | 262,372 | 961,711 | 622,399 | 37.66 | (583.9) |
| 2022 | 4,008,507 | 2,751,454 | 2,724,907 | 2,481,143 | 38.03 | (417.3) |
| 2021 | 29,016,727 | 10,356,288 | 2,888,272 | 1,170,404 | 45.61 | (349.8) |
(1)The following individuals are our NEOs for the following fiscal years ended December 31:
| Year | PEO | Non-PEO NEOs |
| 2023 | Richard Adcock | Dr. Patrick Soon-Shiong and David Sachs |
| 2022 | Richard Adcock | Dr. Patrick Soon-Shiong and David Sachs |
| 2021 | Richard Adcock | Dr. Patrick Soon-Shiong and David Sachs |
(2)Amounts shown in Columns (b) and (d) represent the total compensation reported for Mr. Adcock and an average for our Non-PEO NEOs for each corresponding fiscal year in the “Total” column of the Summary Compensation Table. Values shown above for the fiscal year ended December 31, 2023 do not incorporate equity awards to Mr. Adcock and Dr. Soon-Shiong as no such awards were granted to them during that period. Values shown above for the fiscal year ended December 31, 2022 do not incorporate discretionary cash bonuses and/or performance-based bonuses as no such bonuses were earned by our NEOs during that period.
(3)For more information regarding any year not included in the Summary Compensation Table in this proxy statement, please refer to the Proxy Statement on Form DEF 14A filed with the SEC on April 28, 2023.
ImmunityBio, Inc. | 39 | 2024 Proxy Statement
(4)Amounts shown in Columns (c) and (e) represent the “compensation actually paid” to Mr. Adcock and an average for our Non-PEO NEOs, calculated by adjusting the amounts shown for each corresponding fiscal year in the “Total” column of the Summary Compensation Table as follows:
| Adjustments | Mr. Adcock | Average Non-PEO NEOs |
|---|---|---|
| Deduction for Amounts Reported under the “Stock Awards” column in the Summary Compensation Table for Applicable FY | $— | $(116,729) |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | — | 177,570 |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date | — | 54,119 |
| Deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 78 Fair Value from Prior FY End to Applicable FY End | (140,024) | (51,325) |
| Deduction for Awards Granted during Prior FY that Vested during Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | (754,507) | (402,947) |
| Total adjustments | $(894,531) | $(339,312) |
(5)Amounts shown in Column (f) represent the value of a fixed investment of $100 in the company’s common stock based on cumulative TSR as of the end of each fiscal year. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period (December 31, 2021 – December 31, 2023), assuming dividend reinvestment, and the difference between the share price at the end and the beginning of the measurement period by the share price at the beginning of the measurement period. The company has never paid cash dividends on its common stock. Share price data was collected using S&P Capital IQ.
(6)Amounts shown in Column (h) represent the net loss reported in the company’s audited consolidated financial statements that appear in Part II, Item 8. “Financial Statements and Supplementary Data” of our Annual Report for the fiscal year ended December 31, 2023 filed with the SEC on March 19, 2024.
ImmunityBio, Inc. | 40 | 2024 Proxy Statement
Narrative Disclosure to Pay Versus Performance Table
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.